← Back to Clinical Trials
Recruiting NCT06869915

NCT06869915 Homelessness and Prevalence of Neurodevelopmental Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06869915
Status Recruiting
Phase
Sponsor Hôpital le Vinatier
Condition Neurodevelopmental Disorders
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2026-03-09
Primary Completion 2027-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Prevalence (percentage) of ASD, ADHD and IDD in the studied population (homeless people sheltered in accommodation and social rehabilitation centers).

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2026-03-09 with a primary completion date of 2027-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Introduction \& Central question: Psychiatric disorders are highly prevalent in the homeless population, however neurodevelopmental disorders are also at risk of leading to homelessness (Churchard et al., 2018; Casey et al., 2020). Research on this topic is poor in France. This research aims to study the prevalence in France of 3 neurodevelopmental disorders (NDDs) in a homeless population (Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Intellectual Developmental Disorder). Methods / approach: A 2 phase approach will be used including a screening phase and a diagnosis phase. This research is a pilot study that will include 150 homeless people, over 2 years. The assessment involves combining the results from standardised self-report tools, direct observation and informant-report, thus guaranteeing an objective and thorough diagnosis. This approach gives a better picture of actual behaviour but also a better understanding of the person's development. OUTCOME: This study will give insight on how to better understand the profile of the homeless population in France, and the prevalence of autism in this population. It will also bring valuable knowledge on how autism and other NDDs can impact one's path in life and lead to homelessness. The results can help develop targeted cares and measures for homeless people with NDDs.

Eligibility Criteria

Inclusion Criteria: * Homeless people sheltered in accommodation and social rehabilitation centers * Over 18 years of age * Who speak French * who have given then written informed consent Exclusion Criteria: \- Every person who hasn't given their written informed consent.

Contact & Investigator

Central Contact

Gabrielle CHESNOY

✉ gabrielle.chesnoy@ch-le-vinatier.fr

📞 0033437915380

Principal Investigator

Caroline DEMILY, MdPh

PRINCIPAL INVESTIGATOR

VINATIER HOSPITAL

Frequently Asked Questions

Who can join the NCT06869915 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Neurodevelopmental Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06869915 currently recruiting?

Yes, NCT06869915 is actively recruiting participants. Contact the research team at gabrielle.chesnoy@ch-le-vinatier.fr for enrollment information.

Where is the NCT06869915 trial being conducted?

This trial is being conducted at Lyon, France.

Who is sponsoring the NCT06869915 clinical trial?

NCT06869915 is sponsored by Hôpital le Vinatier. The principal investigator is Caroline DEMILY, MdPh at VINATIER HOSPITAL. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology